Brain-wide quantification of blood-brain barrier penetrating antibody therapeutics - the process of delivering antibody-based therapeutics drugs to the brain is complicated by the need to penetrate…

The National Institute on Aging awarded Translucence Biosystems, Inc. $3,733,679 on September 20, 2025, under the Aging Research program (CFDA 93.866) to develop and refine a vasculature subtraction parenchymal quantification (VSPQ) workflow for measuring antibody therapeutic drug penetration in the brain. This Phase II project grant addresses technological gaps in current methods for quantifying the distribution of antibody-based therapeutics across the blood-brain barrier, which suffer from inadequate accuracy, reliability, and three-dimensional analytical capacity.

Translucence Biosystems will enhance its proprietary 3D brain imaging and analysis platform to create the VSPQ workflow, which uses machine learning algorithms to distinguish between vasculature and brain parenchyma signals, targeting 95 percent sensitivity and specificity relative to human assessments. Specific aims include integrating the VSPQ workflow into the existing 3D imaging platform to correlate AI-generated data with manually partitioned regional data; validating the software's utility through blind analysis of data from strategic partners; and validating a cloud-based version of the pipeline to ensure stability, reliability, and performance consistency with the local version.

Performance of work will occur in Irvine, California. The period of performance runs through May 31, 2027. This is an assistance award under the Project Grant assistance type.

Brain-wide quantification of blood-brain barrier penetrating antibody therapeutics - the process of delivering antibody-based therapeutics drugs to the brain is complicated by the need to penetrate the blood-brain barrier (BBB), prompting interest in BBB-penetrating strategies for antibody therapeutics. However, the methods to test brain penetration of these drugs are inadequate due to the intermingling of blood vessels and brain tissue, which confounds the signal of drug penetration. Current methods for measuring the distribution of antibody drugs in the brain are inadequate, lacking in accuracy, reliability and the capacity for three-dimensional, high-resolution, quantitative analysis. Addressing this technological shortfall, translucence biosystems is enhancing its proprietary 3D brain imaging and analysis platform to create a specialized vasculature subtraction parenchymal quantification (VSPQ) workflow. This tool aims to isolate and measure only the therapeutically relevant antibody drug within the brain parenchyma. The phase II goal is to refine this approach to ensure precise measurement, leveraging the company's experience and expertise in neuroscience, artificial intelligence (AI), and technology commercialization. The specific aims of the project are to develop and qualify the VSPQ workflow using machine learning algorithms to distinguish between vasculature and parenchyma signals, targeting 95% sensitivity and specificity relative to human assessments; integrate the VSPQ workflow into the existing 3D imaging platform, ensuring that the AI-generated data correlates strongly with manually partitioned regional data; validate the utility of the software through blind analysis of data provided by strategic partners, demonstrating its robustness and accuracy in real-world conditions; and validate a cloud- based version of the pipeline, ensuring that IT is stable, reliable, and performs consistently with the local version. The impact of this research is poised to be significant, providing a vital tool for alzheimer's disease drug discovery and potentially improving the rate of successful treatment development. By offering the VSPQ workflow as a cloud-based software-as-a-service, translucence biosystems is aiming to make this innovative technology widely accessible, thereby streamlining the drug development pipeline and bringing new therapies to patients more efficiently.